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OBJECTIVE: Previous studies on risk factors for postoperative
surgical site infections (SSI) have identiﬁed presence of diabetes
as a major risk factor for development of SSI following cardiac
surgery. However, why certain diabetics are more likely to
develop SSI than others is unknown. The purpose of this study
was to identify risk factors and outcomes of SSI in diabetics
undergoing cardiac surgery. METHOD: Nested, case-control
study. Patients with diabetes undergoing coronary artery bypass
or valve replacement surgery at St. Luke’s Episcopal Hospital,
Houston, Texas, who experienced a post-operative SSI (n = 71)
in 2002–2004 were compared to randomly selected, uninfected
controls (n = 103) whom underwent similar surgery during the
same time period. Clinical data was collected to determine risk
factors and outcomes using univariate statistics and multivariate
logistic regression. RESULTS: History of cardiac disorders (con-
gestive heart failure, stroke, angina, or myocardial infarction)
(OR = 1.589; 95% CI = 1.132–2.230; p = 0.0075) and obesity
(OR = 2.849; 95% CI = 1.241–6.542; p = 0.0136) were identi-
ﬁed as signiﬁcant independent risk factors for SSI in diabetics
undergoing cardiac surgery. Cases were hospitalized an average
eight-days longer than uninfected controls (p = 0.0006) and
experienced twice as many complications requiring reoperation
(10.6% vs. 21%; p = 0.057). CONCLUSION: Cardiac history
and obesity were identiﬁed as signiﬁcant risk factors for SSI in
our diabetic patient population. SSI signiﬁcantly increased hos-
pital length of stay in our diabetic population.
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OBJECTIVES: The CREDO trial demonstrated the clinical efﬁ-
cacy of 12-month therapy with clopidogrel, with a 27% RRR (p
= 0.02) combined risk of death, MI, or urgent target revascu-
larization in patients undergoing percutaneous coronary inter-
vention (PCI) and being treated with ASA. The purpose of 
this study was to evaluate the long-term cost-effectiveness of 
12-month versus 28-day therapy with clopidogrel in Sweden.
METHODS: A Markov model was developed, enabling model-
ling over the longer term. A hypothetical cohort of patients in a
post-PCI state was assumed to have certain risks of suffering one
of the endpoints of the CREDO trial: stroke, MI or death. First-
year risks were taken from the observed rates of the CREDO
trial while risks for following years were estimated based on epi-
demiological data, provided by the Centre for Epidemiology at
the Swedish National Board of Health and Welfare. Cost data
was collected from published sources. The perspective was that
of society. Effectiveness was measured as the number of life-years
gained from long-term treatment with clopidogrel. Cost-
effectiveness acceptability curves were created using bootstrap-
ping to estimate parameter uncertainty and Monte Carlo simu-
lation to estimate the effect of this uncertainty in the model.
RESULTS: The model predicted a mean survival of 12.35 years
in the 12-month arm compared to 12.28 in the 28-day arm, an
incremental gain of 0.065 life-years. The increase in survival
came at a predicted incremental cost of 171€, resulting in an
incremental cost-effectiveness ratio (ICER) of 2637€. If only
direct costs were considered, the ICER was 7588€. If costs due
to increased survival were included, the ICER was 14,681€.
Results were insensitive to variations in costs and discount rates.
CONCLUSIONS: The predicted cost-effectiveness ratio of long-
term treatment with clopidogrel in patients undergoing PCI is
well below the threshold values currently considered cost-
effective.
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The search for less gastrointestinal toxic nonsteroidal anti-
inﬂammatory drugs (NSAIDs) led to the introduction of the
selective cyclooxygenase-2 (COX-2) inhibitors. However, with
this introduction into the market, there have been concerns
regarding their safety, particularly cardiovascular safety. OBJEC-
TIVE: The purpose of this study was to assess the cardiovascu-
lar risk (events included: myocardial infarction, stroke, and
myocardial infarction-related deaths) associated with long-term
use (after 180 days of exposure) of nonselective NSAIDs and
COX-2 inhibitors. METHODS: A retrospective analysis of the
Veterans Integrated Service Network 17 Veteran’s Affairs (VA)
database was conducted. Medicare data and Department of
Health mortality data were incorporated to capture events occur-
ring outside the VA health care network. Patients 35 years of age
and older receiving celecoxib, rofecoxib, ibuprofen, etodolac,
and naproxen from January 1, 1999 through December 31,
2001, were included. Multivariate Cox proportional hazard
models were used to analyze the relationship between cardio-
vascular risk and NSAID/COX-2 inhibitor use while adjusting
for various demographic and co-morbidity factors. RESULTS:
We identiﬁed 6814 long-term exposure periods and 42 cardio-
vascular events over the study period. Compared to long-term
ibuprofen use, long-term use of celecoxib was associated with a
3.64 fold (95% CI 1.36–9.70; p = 0.01) increase in cardiovas-
cular risk. Long-term use of rofecoxib was associated with a 6.64
fold (95% CI 2.17–20.28; p = < 0.01) increased risk when com-
pared to long-term users of ibuprofen. Long-term exposure to
naproxen and etodolac was not associated with a cardionegative
or cardioprotective effect when compared to long-term ibupro-
fen users. CONCLUSIONS: The ﬁndings of this observational
study along with recent clinical trial results suggest that 
long-term exposure to COX-2 inhibitors is associated with 
an increased cardiovascular risk. In addition, the study results
do not show that naproxen or etodolac provide a cardioprotec-
tive or cardionegative effect.
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OBJECTIVE: Estimate direct medical costs of Urinary Inconti-
nence (UI), namely Stress Urinary Incontinence (SUI), Mixed
